CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts won the Facilities of the Year Award (FOYA) award in 2022. The company’s lead program, Exagamglogene autotemcel, or exa-cel (formerly CTX001), has been submitted for regulatory approval in 2023. More information...
According to PR-model, crisprtx.com is ranked 797,726th in multilingual Wikipedia, in particular this website is ranked 601,336th in English Wikipedia.
The website is placed before etm-testmagazin.de and after kpitb.gov.pk in the BestRef global ranking of the most important sources of Wikipedia.
